OptimizeRx Corp (OPRX)
| Market Cap | 155.77M-54.7% |
| Revenue (ttm) | 98.65M |
| Net Income | 4.60M |
| EPS | 0.24 |
| Shares Out | 18.84M |
| PE Ratio | 34.46 |
| Forward PE | 7.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,192 |
| Open | 8.52 |
| Previous Close | 8.55 |
| Day's Range | 8.25 - 8.52 |
| 52-Week Range | 4.54 - 22.25 |
| Beta | 1.26 |
| Analysts | Strong Buy |
| Price Target | 12.60(+52.36%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 11 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About OPRX
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
$OPRX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OPRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OPRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OPRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New OPRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OPRX from public contracts
Source: USAspending.gov
OPRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OPRX’s recent data — informational, not investment advice
